Clinical Trial Applications - Stopped: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Stopped | |
|---|---|---|---|---|---|
41. |
ECCT/22/07/01 | GBT021601-021 Study A Phase 2/3 Randomized, Multicenter Study of GBT021601 Administered Orally to Participants with Sickle Cell Disease and an Open-Label Pharmacokinetics Study in Pediatric Participants with Sickle Cell Disease |
Principal Investigator(s) 1. Jessie Nyokabi Githanga 2. Berhnards Ragama Ogutu 3. Videlis Nduba 4. Berhnards Ragama Ogutu Site(s) in Kenya 1. Gertude\'s Children\'s Hospital (Nairobi City county) 2. CENTER FOR RESEARCH IN THERAPEUTIC SCIENCES-STRATHMORE UNIVERSITY MEDICAL CENTER (CREATES (Nairobi City county) 3. / KENYA MEDICAL RESEARCH INSTITUTE- CENTER FOR RESPIRATORY DISEASE RESEARCH(CRDR) (Nairobi City county) 4. KENYA MEDICAL RESEARCH INSTITUTE- SIAYA COUNTY REFERAL HOSPITAL (Siaya county) |
Not recorded |
View |
42. |
ECCT/20/12/03 | CALINA STUDY A multicenter, open-label, single-arm study to evaluate the PK, safety, tolerability and efficacy of a new artemether-lumefantrine (2.5 mg:30 mg) dispersible tablet in the treatment of infants and neonates <5 kg body weight with acute uncomplicated Plasmodium falciparum malaria. Study number: CCOA566B2307 |
Principal Investigator(s) 1. Benhards Ragama Ogutu Site(s) in Kenya KEMRI-Centre for Clinical Research (CCR) |
Not recorded |
View |
43. |
ECCT/18/07/05 | A Multi-country, Prospective, Clinical Safety Study of Subjects Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo A Multi-country, Prospective, Clinical Safety Study of Subjects Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo |
Principal Investigator(s) 1. Fredrick Sawe 2. Janet Oyieko Site(s) in Kenya 1. Kenya Medical Research Institute/Walter Reed Project, Clinical Research Centre (Kericho county) 2. KEMRI/WRP Kisumu, Kenya at the Kombewa Clinical Research Centre (Kisumu county) |
Not recorded |
View |
44. |
ECCT/22/08/02 | AIM-LVRNA009-II_III-01 A Global Multi-center, Randomized, Blinded, Placebo-controlled Phase 2/3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (LVRNA009) for the Prevention of COVID-19 in Participants Aged 18 Years and Olde |
Principal Investigator(s) 1. Bernhards Ogutu 2. Lucas Otieno 3. Videlis Nduba 4. Bernhards Ogutu 5. Jacqueline Mirera 6. Jacqueline Mirera Site(s) in Kenya 1. Siaya Clinical Trials Unit (Siaya county) 2. Homa Bay Clinical Trials Unit (Homa Bay county) 3. Ahero Clinical Trials Unit (Kisumu county) 4. CREA-N Machakos (Machakos county) 5. CREA-N Nakuru (Nakuru county) 6. Victoria Biomedical Research Institue (Kisumu county) |
Not recorded |
View |
45. |
ECCT/11/02/01 | Compare the Efficacy and Safety of Gentian Violet to that of Nystatin A5265 - A Phase III, Open-Label, Randomized, Assessment-Blinded Clinical Trial to Compare the Safety and Efficacy of Topical Gentian Violet to that of Nystatin Oral Suspension for the Treatment of Oropharyngeal Candidiasis in HIV-1 Infected Participants in Non-U.S. Settings |
Principal Investigator(s) 1. Abraham Mosigisi Siika Site(s) in Kenya 1. Moi University Clinical Research Centre (Uasin Gishu county) 2. KEMRI Walter Reed Project (Kericho county) |
Not recorded |
View |
46. |
ECCT/17/06/02 | PAINT Study A Phase II, open label, single arm trial to evaluate the pharmacokinetics, safety, tolerability, and antiviral activity of rilpivirine (TMC278) in antiretroviral-naïve HIV-1 infected adolescents and children aged ≥6 to <18 years |
Principal Investigator(s) 1. Isaac Tsikhutsu Site(s) in Kenya 1. Kenya Medical Research Institute/Walter Reed Project, HIV Program (Kericho county) 2. KAVI Institute of Clinical Research (Nairobi City county) |
Not recorded |
View |
47. |
ECCT/23/02/04 | mRNA-1273-P203 A Phase 2/3, Randomized, Observer-Blind, Placebo‑Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA‑1273 SARS‑CoV‑2 Vaccine in Healthy Adolescents 12 to <18 Years of Age |
Principal Investigator(s) 1. Dr Victor Mudhune Site(s) in Kenya 1. Victoria Biomedical Research Institute (Kisumu county) 2. KEMRI/USAMRD (Kericho county) 3. Kenya Medical Research Institute/USAMRU (Kisumu county) 4. KEMRI CMR-Kar Geno Research Centre (Kisumu county) 5. KEMRI CMR-Kar Geno Research Centre (Kisumu county) 6. KEMRI CRDR - Clinical Research Nairobi (Nairobi City county) 7. KEMRI/ CDC (Kisumu county) 8. KEMRI (Kisumu county) 9. KEMRI Centre for Clinical Research Butere County Hospital (Kakamega county) 10. KAVI Institute of Clinical Reasearch, College of Health science (Nairobi City county) |
Not recorded |
View |
48. |
ECCT/23/05/05 | mRNA-1273-P203 A Phase 2/3, Randomized, Observer-Blind, Placebo‑Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA‑1273 SARS‑CoV‑2 Vaccine in Healthy Adolescents 12 to <18 Years of Age |
Principal Investigator(s) 1. Videlis Nduba Site(s) in Kenya 1. KEMRI CRDR - Clinical Research Nairobi (Nairobi City county) 2. KEMRI/USAMRD (Kericho county) 3. Victoria Biomedical Research Institute (Kisumu county) 4. Kenya Medical Research Institute/USAMRU (Kisumu county) 5. KEMRI CMR-Kar Geno Research Centre (Kisumu county) 6. KEMRI/ CDC (Kisumu county) 7. KEMRI (Kisumu county) 8. KEMRI Centre for Clinical Research Butere County Hospital (Kakamega county) 9. KAVI Institute of Clinical Reasearch, College of Health science (Nairobi City county) |
Not recorded |
View |
49. |
ECCT/23/04/01 | mRNA-1273-P203 A Phase 2/3, Randomized, Observer-Blind, Placebo‑Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA‑1273 SARS‑CoV‑2 Vaccine in Healthy Adolescents 12 to <18 Years of Age |
Principal Investigator(s) 1. Dr Janet Oyieko Site(s) in Kenya 1. KEMRI Centre for Clinical Research Butere County Hospital (Kakamega county) 2. KEMRI CRDR - Clinical Research Nairobi (Nairobi City county) 3. KEMRI/USAMRD (Kericho county) 4. Victoria Biomedical Research Institute (Kisumu county) 5. Kenya Medical Research Institute/USAMRU (Kisumu county) 6. KEMRI CMR-Kar Geno Research Centre (Kisumu county) 7. KEMRI/ CDC (Kisumu county) 8. KEMRI (Kisumu county) 9. KAVI Institute of Clinical Reasearch, College of Health science (Nairobi City county) |
Not recorded |
View |
50. |
ECCT/23/09/03 | CONSTELLATION A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the effect of Bi-26 (strain of Bifidobacterium longum, B. infantis) supplementation versus placebo on weight gain in underweight infants |
Principal Investigator(s) 1. Dr Simon Kariuki Site(s) in Kenya 1. Kenya Medical Research Institute- Centre for Global Health Research (Kisumu county) |
Not recorded |
View |